Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Halozyme Therapeutics, Inc.

http://www.halozyme.com

Latest From Halozyme Therapeutics, Inc.

India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’

Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.

India Intellectual Property

India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities

Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.

Regulation Intellectual Property

India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’

Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.

India Intellectual Property

Hopes For A ‘New Era’ In UK Biotech Financing With Pension-Backed Fund

Backed by the UK government and the Phoenix Group, the initial £200m fund is aimed at convincing pension funds to invest in the higher-risk, higher-reward life sciences sector.

Commercial Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Antares Pharma, Inc.
UsernamePublicRestriction

Register